Skip to main content
. 2017 Nov 18;8(63):106565–106576. doi: 10.18632/oncotarget.22497

Figure 5. TAB3, TRAF6 and TAK1 are involved in NF-κB activation.

Figure 5

(A–C) co-IP among endogenous TAB3, TAK1 and TRAF6 in SW480 cells. (D–I) co-IP and Western blot analysis showing the levels of TAB3, TAK1 and TRAF6 after silencing or overexpression and their effects on TAB3, TAK1 and TRAF6 interaction and the NF-κB pathway in CRC cells. (J–K) Western blot and Luciferase analysis showing the levels of TAB3, TAK1 and TRAF6 after silencing and their effects on p-IKBa and p-P65 expression and NF-κB activity in SW480 cells (**P < 0.01). (L–M) Western blot and Luciferase analysis showing the levels of TAB3, TAK1 and TRAF6 after overexpression and their effects on p-IKBa and p-P65 expression and NF-κB activity in HCT-116 cells (**P < 0.01).